Combination Faslosdex and Arimidex success in Breast Cancer trial

A report in 2 August issue of NEJM recorded that a combination of Arimidex ( anastrozole) and oestrogen receptor modulator Faslodex (fluvestrant) is more effective than either Arimidex or Faslodex alone or sequentially administered in treating post menopausal hormone recepttor (HR) positive metastatic breast cancer. Combination therapy gave a signiicant improvement in secondary endpoint of overall survival by more than 6 months. see "Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer"-Rita S. Mehta, M.D., William E. Barlow, Ph.D., Kathy S. Albain, M.D., Ted A. Vandenberg, M.D., Shaker R. Dakhil, M.D., Nagendra R. Tirumali, M.D., Danika L. Lew, M.A., Daniel F. Hayes, M.D., Julie R. Gralow, M.D., Robert B. Livingston, M.D., and Gabriel N. Hortobagyi, M.D.N Engl J Med 2012; 367:435-444 August 2, 2012